Insights

Actinogen Medical (ASX:ACW) share price jumps on patent news

The Actinogen Medical Ltd (ASX: ACW) share price jumped 4.5% on open this morning, after the company announced it has filed two new patent applications to strengthen and extend its intellectual property (IP) portfolio.   What does Actinogen Medical do? Actinogen Medical is an ASX biotech company. It specialises in developing novel therapies of a range
The post Actinogen Medical (ASX:ACW) share price jumps on patent news appeared first on Motley Fool Australia. –

share price jump

The Actinogen Medical Ltd (ASX: ACW) share price jumped 4.5% on open this morning, after the company announced it has filed two new patent applications to strengthen and extend its intellectual property (IP) portfolio.  

What does Actinogen Medical do?

Actinogen Medical is an ASX biotech company. It specialises in developing novel therapies of a range of conditions. These include neurological, psychiatric and metabolic diseases associated with chronically elevated cortisol. This is a metabolic disorder caused by overproduction of corticosteroid hormones by the adrenal cortex. Often it is associated with obesity and high blood pressure.

The lead compound currently being developed by Actinogen is called “Xanamem”. This compound is a new type of therapy for Alzheimer’s disease, Fragile X syndrome, schizophrenia and diabetes. According to the company, solutions to effectively address these conditions and the burdens for patients have not yet adequately been met. It is therefore focusing on the gap in this market.

Why are these patents important?

The two patents filed this week are to expand and extend the company’s IP estate. 

The first patent filed requests protection for a method of improving cognition or treating cognitive decline in cognitively healthy subjects. Expansion of the IP estate is a key goal here.

The second patent filed provided protection to a commercial scale-up manufacturing process for Xanamem. This patent is the result of a collaborative effort between Actinogen Medical and a Switzerland-based contract development and manufacturing organisation.

Actinogen holds a large number of patents, either granted or pending. The new patents filed this week have the ability to extend patent life. Protection around Xanamem is now effective until 2040 at least. This gives the company a long runway of breathing room to continue its research and development.

In statement to the ASX today, Actinogen Medical CEO and managing director Dr Bill Ketelbey had this to say:

Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy for Xanamem. The potential to treat cognitively healthy subjects, a population in which XanaHES demonstrated clear efficacy results, as well as treat those at risk of cognitive impairment, is a significant medical and commercial opportunity. Equally, the patented and optimised manufacturing methodology provides an efficient and commercially viable process which provides a substantial new barrier to competition. Actinogen remains focused on maintaining and extending the protection of Xanamem to maximise its commercial potential.

Foolish takeaway

The Actinogen Medical share price opened 4.5% higher on this positive news today. However, overall this year the Actinogen Medical share price is down more than 30%. 

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor glennleese has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Actinogen Medical (ASX:ACW) share price jumps on patent news appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!